Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...
A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.
Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
Q3 2025 Earnings Call Transcript October 29, 2025 OPKO Health, Inc. beats earnings expectations. Reported EPS is $0.03, ...
MedPage Today on MSN
Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer
Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...
It’s fitting, then, that this year’s GlobeDocs Festival — hosted by the Globe and running in person Oct. 22–26 — should ...
(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...
Q3 2025 Earnings Call October 23, 2025 4:00 AM EDTCompany ParticipantsPascal Daloz - CEO & DirectorRouven Bergmann ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback